Skip to content
DataLookout
Menu

NCT06617923

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 52 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 2 of 2 sites
  2. Minor Study sites: 1 to 2v8
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2025 to Feb 6, 2025
    v7
  4. Minor Start date: Jan 2025 to Feb 2025
    • Study title expanded, about 6 words
    v5
  5. Minor Start date: Dec 2024 to Jan 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Start date: Nov 2024 to Dec 2024v3
  2. Minor Start date: Oct 2024 to Nov 2024v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: 3 years

Secondary (2)

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Frequency of Grade 3 and 4 Adverse Events

Arms and interventions

TreatmentExperimental

Senaparib 80mg Temozolomide 20mg

Drugs: Senaparib, Temozolomide

Sites

2 sites in 1 country